Nelson Christopher M. 4
4 · QSAM Biosciences, Inc. · Filed Feb 13, 2024
Insider Transaction Report
Form 4
Nelson Christopher M.
DirectorCEO
Transactions
- Conversion
Common Stock
2024-02-06$3.00/sh+8,683$26,049→ 182,000 total - Conversion
Series B Convertible Preferred Stock
2024-02-06→ 0 totalExercise: $3.00From: 2021-01-27→ Common Stock (8,683 underlying)
Holdings
- 12,500
Options to buy common stock
Exercise: $10.00Exp: 2032-03-03→ Common Stock (12,500 underlying) - 2,875
Options to buy common stock
Exercise: $14.40Exp: 2031-08-23→ Common Stock (2,875 underlying) - 60
Options to buy common stock
Exercise: $20.00From: 2015-11-18Exp: 2025-11-18→ Common Stock (60 underlying) - 255
Options to buy common stock
Exercise: $20.00From: 2014-07-31Exp: 2024-07-31→ Common Stock (255 underlying)
Footnotes (3)
- [F1]The Series B Convertible Preferred Stock was convertible into common stock at any time and had no expiration date. Pursuant to an Exchange Agreement signed by and between the Company and all Series B Preferred Stockholders as of 11/18/23, the Series B Preferred Stock was automatically exchangeable for common stock of the Issuer at a price of $3.00 per share upon the Issuer listing on Nasdaq or signing an agreement to be acquired.
- [F2]The option vests annually in two equal installments beginning on 3/3/2023.
- [F3]The option vested semi-annually in two equal installments beginning on 2/24/2022.